Oncos Therapeutics Raises €4 Million from Healthcap to Develop Oncolytic Viruses into Cancer Treatments
News Apr 29, 2010

Oncos Therapeutics, a biotech company developing new cancer therapeutics based on its next generation oncolytic viruses, completed a € 4 million ($ 5.5 million) investment from HealthCap. With committed capital exceeding € 800 million, HealthCap is one of the largest specialized providers of venture capital within life sciences in Europe.
After treating 200 late stage cancer patients since 2007 with strong safety and efficacy results, Oncos has selected its modified oncolytic adenovirus CGTG-102 as its lead clinical candidate. “This is the first step to turn our Advanced Therapy Access Program results into cancer therapeutics”, comments Pekka Simula, CEO and co-founder.
“The results have been strong for late stage solid tumor cancers where routine therapies have failed. Time is critical in the treatment of cancer. We are confident that when treating earlier stage patients, our oncolytic virus therapy will prove even more significant”, continues Research Professor Akseli Hemminki, CSO and co-founder.
“Oncolytic viruses are maturing as a new treatment modality in cancer. Oncos, as one of the leading companies in the field, and combines very promising results in humans with strong science”, comments Dr Johan Christensen, partner at HealthCap.
RELATED ARTICLES
Fermentation Byproduct Suppresses Seizures in Nerve Agent Poisoning
NewsA compound found in trace amounts in alcoholic beverages is more effective at combating seizures in rats exposed to an organophosphate nerve agent than the current recommended treatment.
READ MOREPhoreMost and Plexxikon Collaborate to Identify Novel Drug Targets
NewsPhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.
READ MOREAnti-Malaria Drugs Delivered With Caffeine
NewsMany drug delivery systems, such as capsules and tablets, can be difficult to swallow, especially for children. Making delivery systems out of polymer gels is an attractive option, but usually requires hazardous levels of heavy metals to be used. Now, scientists have found a way to build these gels from caffeine molecules.
READ MOREComments | 0 ADD COMMENT
To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREEWorld Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018
Login
You must be logged in to post a comment.